CME Activities

Coming soon...

CLICK ON STATES TO SEE GRAND ROUNDS ACTIVITIES

VIRTUAL SUMMIT MEETINGS

Feb
16
Tue
The RELIEF Initiative – Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic – Jon T. Giles, MD, MPH and Andreas Reimold, MD
Feb 16 @ 7:00 pm – 8:30 pm

Tuesday, February 16, 2021

7:00PM – 8:30PM ET

Please note this virtual program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.

Faculty

Jon T Giles, MD, MPH
Associate Professor of Medicine
Columbia University
Vagelos School of Physicians & Surgeons
New York, NY

Andreas Reimold, MD
Professor, Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

View Activity

Feb
20
Sat
The RELIEF Initiative – Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic – Daniel Furst, MD and Silvia Bellando-Randone, MD
Feb 20 @ 9:00 am – 10:30 am

Saturday, February 20, 2021

9:00AM – 10:30AM ET

Please note this virtual program is 9:00AM Eastern, 8:00AM Central, 7:00AM Mountain and 6:00AM Pacific.

Faculty

Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles, CA
University of Washington, Seattle, WA
University of Florence, Florence, Italy

Silvia Bellando-Randone, MD
Department of Experimental and Clinical Medicine
University of Florence
Department of Geriatric Medicine, Division of Rheumatology and Scleroderma Unit AOUC
Florence, Italy

View Activity

Mar
3
Wed
The RELIEF Initiative – Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic – Daniel Furst, MD and Andreas Reimold, MD
Mar 3 @ 7:00 pm – 8:30 pm

Wednesday, March 3, 2021

7:00PM – 8:30PM ET

Please note this virtual program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.

Faculty

Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles, CA
University of Washington, Seattle, WA
University of Florence, Florence, Italy

Andreas Reimold, MD
Professor, Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

View Activity

ONLINE PROGRAMS

Feb
18
Tue
RELIEF: The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment
Feb 18 2020 @ 1:00 pm Feb 18 2021 @ 2:00 pm

RELIEF: The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment

FACULTY

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Daniel J. Wallace, MD, FACP, MACR
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

PROGRAM OVERVIEW

This case-based enduring activity will cover the treatment and management of patients with axial spondyloarthritis.

TARGET AUDIENCE

This activity is intended for rheumatologists and other healthcare professionals involved in the management of patients with axial spondyloarthritis.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Examine the specific domains of axial spondyloarthritis (AxSpA) and their relationship to quality of life
  • Review current and emerging therapies used for AxSpA
  • Evaluate the IL-17/23 axis and its relationship to the pathophysiology of AxSpA
  • Compare outcomes measures used in clinical trials versus those that may be more practical for use in clinical practice

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 1.5 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with axial spondyloarthritis.
CNE Credits: 1.5 ANCC Contact Hours.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Leonard H. Calabrese, DO has received consulting fees from AbbVie, Genentech, Gilead, Horizon, Janssen, Lilly, Novartis, and Pfizer, and has served on speaker’s bureaus for AbbVie, Genentech, Horizon, Janssen, Lilly, and Novartis.

Daniel J. Wallace, MD, FACP, MACR has nothing to disclose.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, Medical Director of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: February 18, 2020

EXPIRATION DATE: February 18, 2021

Jul
26
Sun
RELIEF: The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment
Jul 26 2020 @ 1:00 pm Jul 26 2021 @ 2:00 pm

RELIEF: The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment

FACULTY

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
RJ Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

PROGRAM OVERVIEW

This activity is primarily designed for US-based members of multidisciplinary teams involved in the management of patients with Axial Spondyloarthritis (AxSpA).

TARGET AUDIENCE

This activity is intended for rheumatologists and other healthcare professionals involved in the management of patients with axial spondyloarthritis.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Examine the specific domains of AxSpA and their relationship to quality of life
  • Review current and emerging therapies used for AxSpA
  • Evaluate the IL-17/23 axis and its relationship to the pathophysiology of AxSpA

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in treating and managing patients with Axial Spondyloarthritis.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY
Leonard H. Calabrese, DO has received consulting fees from AbbVie, Genentech, Gilead, Horizon, Janssen, Lilly, Novartis, and Pfizer, and has served on speaker’s bureaus for AbbVie, Genentech, Horizon, Janssen, Lilly, and Novartis.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.

Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.

Lisa Crenshaw, Program Manager for Med Learning Group, has nothing to disclose.

Chris Drury, Scientific and Medical Services for Med Learning Group, has nothing to disclose.

Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 26, 2020

EXPIRATION DATE: July 26, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

SUMMIT MEETINGS

Feb
16
Tue
The RELIEF Initiative – Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic – Jon T. Giles, MD, MPH and Andreas Reimold, MD
Feb 16 @ 7:00 pm – 8:30 pm

Tuesday, February 16, 2021

7:00PM – 8:30PM ET

Please note this virtual program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.

Faculty

Jon T Giles, MD, MPH
Associate Professor of Medicine
Columbia University
Vagelos School of Physicians & Surgeons
New York, NY

Andreas Reimold, MD
Professor, Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

View Activity

Feb
20
Sat
The RELIEF Initiative – Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic – Daniel Furst, MD and Silvia Bellando-Randone, MD
Feb 20 @ 9:00 am – 10:30 am

Saturday, February 20, 2021

9:00AM – 10:30AM ET

Please note this virtual program is 9:00AM Eastern, 8:00AM Central, 7:00AM Mountain and 6:00AM Pacific.

Faculty

Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles, CA
University of Washington, Seattle, WA
University of Florence, Florence, Italy

Silvia Bellando-Randone, MD
Department of Experimental and Clinical Medicine
University of Florence
Department of Geriatric Medicine, Division of Rheumatology and Scleroderma Unit AOUC
Florence, Italy

View Activity

Mar
3
Wed
The RELIEF Initiative – Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic – Daniel Furst, MD and Andreas Reimold, MD
Mar 3 @ 7:00 pm – 8:30 pm

Wednesday, March 3, 2021

7:00PM – 8:30PM ET

Please note this virtual program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.

Faculty

Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles, CA
University of Washington, Seattle, WA
University of Florence, Florence, Italy

Andreas Reimold, MD
Professor, Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

View Activity

GRAND ROUNDS

Feb
19
Fri
Grand Round @ Mayfield Heights, OH
Feb 19 @ 8:00 am – 9:00 am

Meeting Date
Friday, February 19, 2021
8:00 – 9:00 AM

Location
University Hospitals Cleveland –
Allergy/Immunology Associates
Mayfield Heights, OH

Speaker
Jon T Giles, MD, MPH

Mar
10
Wed
Grand Round @ Hoboken, NJ
Mar 10 @ 11:30 am – 12:30 pm

Meeting Date
Wednesday, March 10, 2021
11:30 – 12:30 PM

Location
Hoboken University Medical Center
Hoboken, NJ

Speaker
Jon T Giles, MD, MPH

Mar
11
Thu
Grand Round @ Yonkers, NY
Mar 11 @ 8:00 am – 9:00 am

Meeting Date
Thursday, March 11, 2021
8:00 – 9:00 AM

Location
Saint Joseph’s Medical Center
Yonkers, NY

Speaker
Elaine Tozman, MD

Mar
19
Fri
Grand Round @ Decatur, GA
Mar 19 @ 12:15 pm – 1:15 pm

Meeting Date
Friday, March 19, 2021
12:15 – 1:15 PM

Location
Emory Decatur Hospital
Decatur, GA

Speaker
Jon T Giles, MD, MPH

Mar
24
Wed
Grand Round @ Prescott, AZ
Mar 24 @ 8:00 am – 9:00 am

Meeting Date
Wednesday, March 24, 2021
8:00 – 9:00 AM

Location
Northern Arizona VA Health Care System
Prescott, AZ

Speaker
Daniel George Arkfeld, MD

Mar
31
Wed
Grand Round @ Augusta, GA
Mar 31 @ 2:00 pm – 3:00 pm

Meeting Date
Wednesday, March 31, 2021
2:00 – 3:00 PM

Location
Augusta University – Rheumatology Division
Augusta, GA

Speaker
Daniel Furst, MD

Apr
1
Thu
Grand Round @ Sheridan, WY
Apr 1 @ 9:00 am – 10:00 am

Meeting Date
Thursday, April 1, 2021
9:00 – 10:00 AM

Location
Sheridan VA
Sheridan, WY

Speaker
Elaine Tozman, MD

Apr
7
Wed
Grand Round @ Nashville, TN
Apr 7 @ 2:00 pm – 3:00 pm

Meeting Date
Wednesday, April 7, 2021
2:00 – 3:00 PM

Location
Meharry Medical College
Nashville, TN

Speaker
Andreas Reimold, MD

Apr
8
Thu
Grand Round @ Elizabeth, NJ
Apr 8 @ 9:00 am – 10:00 am

Meeting Date
Thursday, April 8, 2021
9:00 – 10:00 AM

Location
Trinitas Regional Medical Center
Elizabeth, NJ

Speaker
Mohamad Bittar, MD

Apr
22
Thu
Grand Round @ Terre Haute, IN
Apr 22 @ 8:00 am – 9:00 am

Meeting Date
Thursday, April 22, 2021
8:00 – 9:00 AM

Location
Union Health
Terre Haute, IN

Speaker
Elaine Tozman, MD

Scroll to Top

Updates in the Treatment and Prevention of COVID-19

Emergency use authorization for casirivimab/imdevimab in patients with mild-to-moderate COVID-19

The combination of the monoclonal antibodies casirivimab and imdevimab (previously known as REGN-COV2) has been authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (≥12 years of age and ≥40 kg) who are at high risk for progressing to severe COVID-19 or hospitalization.1

Interim results from 275 nonhospitalized patients in a placebo-controlled trial of casirivimab plus imdevimab found that the combination therapy reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Patients who received casirivimab/imdevimab required fewer medical visits for COVID-19 than patients who received placebo (3% vs 6%, respectively). Among patients who were serum antibody-negative at baseline, 15% in the placebo group and 6% in the treatment group required COVID-19-related medical care.2

Baricitinib in combination with remdesivir authorized for emergency use in hospitalized patients

Baricitinib, in combination with remdesivir, is authorized for emergency use in adult and pediatric patients ≥2 years of age hospitalized for COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).3

A recent trial of 1033 patients hospitalized for COVID-19 found that baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time (7 days vs 8 days, respectively; P= .03). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination therapy and 18 days with the control (rate ratio for recovery, 1.51). The addition of baricitinib to remdesivir was associated with 30% higher odds of improvement in clinical status at day 15 compared with remdesivir alone.4

References

  1. Emergency use authorization (EUA) of casirivimab and imdevimab. Available at www.fda.gov/media/143892/download. Accessed 12/23/2020.
  2. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2020;Dec 17:Epub ahead of print. Available at www.nejm.org/doi/full/10.1056/NEJMoa2035002. Accessed 12/23/2020.
  3. Emergency use authorization (EUA) of baricitinib. Available at www.fda.gov/media/143823/download. Accessed 12/23/2020.
  4. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020;Dec 11:Epub ahead of print. Available at www.nejm.org/doi/full/10.1056/NEJMoa2031994. Accessed 12/23/2020.